Nonviral gene delivery system
1★★ Corresponding author
- 1Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, 10627 Diebold Road, Fort Wayne, IN 46845, USA.
CORRESPONDENCE
Ningning Yang
Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, 10627 Diebold Road, Fort Wayne, IN 46845, USA.
Volume 2, Issue 3 · pp. 97-98 · 2012 · DOI: 10.4103/2230-973X.104388
ABSTRACT
Gene therapy has been investigated a lot in both basic research and clinical trials.[1] The first antisense oligodeoxyribonucleotide (ODN) drug, Vitravene (Fomivirsen), was approved by the United States Food and Drug Administration (FDA) in 2005.[2] After this approval, more and more clinical trials are conducted, not only for ODNs, but also for other nucleic acids drugs, such as plasmid vectors and small interference RNAs (siRNAs).
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Yang, N. (2012). Nonviral gene delivery system. International Journal of Pharmaceutical Investigation, 2(3), 97-98. https://doi.org/10.4103/2230-973X.104388
Copyright and licence
© 2012 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0